Background: Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non-small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real-world data of ALK TKIs remain a major concern.
Methods: Patients with ALK-positive advanced NSCLC, who received crizotinib or alectinib treatment in first line, were retrospectively reviewed. ALK status was detected using immunohistochemistry (IHC) or next-generation sequencing (NGS). Clinical outcomes have been comprehensively analyzed between TKIs, ALK fusions, EML4-ALK variants, and next-generation TKIs after crizotinib failure.
Results: One hundred sixty-eight patients were successively enrolled (crizotinib, n = 109; alctinib, n = 59). Alectinib showed consistent superiority in progressive-free survival (PFS) over crizotinib (hazard ratio [HR]: 0.43, 95% confidential interval [CI]: 0.24-0.77, p = 0.004). Multivariate Cox regression showed chemotherapy (CT) prior to TKIs or synchronous chemotherapy seemed not to improve PFS compared to ALK inhibitors alone (p > 0.05). And, alectinib was superior to crizotinib in prolonging intracranial PFS (HR 0.12, 95% CI: 0.03-0.49, p = 0.003). Patients in EML4 group had a better prognosis than those in non-EML4 group after alectinib administration (HR 0.13, 95% CI: 0.03-0.60, p = 0.009). TP53 co-mutations were relatively common (34.0%) and associated with adverse outcome in ALK-positive patients (adjusted HR 2.22, 95% CI: 1.00-4.92, p = 0.049). After crizotinib failure, 33 patients received a sequential application of next-generation ALK TKIs. Compared to ceritinib and brigatinib, alectinib might have better PFS (p = 0.043).
Conclusion: Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741982 | PMC |
| http://dx.doi.org/10.1002/cam4.4834 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report.
JTO Clin Res Rep
December 2024
Department of Oncology, University College London Hospital NHS Foundation Trust, London, United Kingdom.
A 72-year-old man presented to his general practitioner with worsening dyspnea and was diagnosed with having recurrent -positive stage IIIB NSCLC 8 years after initial diagnosis and radical treatment for early stage disease. He was subsequently started on entrectinib but required hospital admissions for recurrent acute kidney injuries on a background of chronic kidney disease. His entrectinib was withheld on day 20 since his first dose of treatment while he was being investigated.
View Article and Find Full Text PDFResponse to Crizotinib After Entrectinib Resistance in -Rearranged, -Amplified Lung Adenocarcinoma.
JCO Precis Oncol
October 2024
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.
View Article and Find Full Text PDFALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
JTO Clin Res Rep
September 2024
Royal North Shore Hospital, St Leonards, Australia.
Article Synopsis
- ALK-positive lung cancers exhibit molecular diversity and pose challenges due to treatment resistance, prompting the need for innovative strategies using ctDNA monitoring.
- The ALKTERNATE pilot study analyzed alternating treatments of lorlatinib and crizotinib in patients resistant to previous ALK inhibitors, focusing on outcomes like treatment failure time, safety, and patient experiences.
- Results showed that the alternating therapy was safe and effective for most participants, with an average treatment failure time of 10 months and overall survival of 23 months, indicating the importance of genetic factors in treatment response.
The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis.
Cell Death Dis
August 2024
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
Article Synopsis
- Crizotinib, a cancer medication, can harm the liver and its side effects, like liver failure, might not be reported well enough.
- Researchers found that Crizotinib causes liver damage mainly through a process called ferroptosis, which is a type of cell death.
- They discovered ways to protect the liver from this harm, like using special drugs and improving a protein called Nrf2, which can help keep the liver safe during treatment.
Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer.
Front Pharmacol
July 2024
Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Background: Despite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred in non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall survival. Unfortunately, durable drug response has not been reported in posterior-line therapy of cases with acquired fusion after resistance to osimertinib, urging the need of referable decision-making in clinical management.
Case Presentation: We present a case of a 71-year-old Chinese female, never smoker, diagnosed with invasive adenocarcinoma in the left inferior lobe of her lung, with metastases in regional lymph nodes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!